Yao Zhang

Yao Zhang

Auto-generated profile, based on publicly available information

Yao Zhang

Department of Medical Oncology Fudan University Shanghai Cancer Center Shanghai China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in Thoracic Cancer
Verified
Journal Article
Open access
YZYao Zhang
Yao Zhang
HLHuiting Li
Huiting Li
BYBo Yu
Bo Yu
SSSi Sun
Si Sun
ZHZhihuang Hu
Zhihuang Hu
HYHui Yu
Hui Yu
Background: Neoadjuvant chemoimmunotherapy (NCIT) for locally advanced esophageal squamous cell carcinoma (ESCC) is supported by increasing data, but the sample size is limited, and the findings are not completely consistent. We conducted a real‐world study and a meta‐analysis to evaluate the efficacy and safety of NCIT in locally advanced ESCC.Methods: We retrospectively assessed the outcomes of patients with locally advanced ESCC who completed NICT and subsequent esophagectomy at our hospital between January 2019 and December 2022, including pathological complete response (pCR) rate, major pathological response (MPR) rate, 1‐, 2‐, and 3‐year overall survival (OS) rates, disease control rate (DCR), objective response rate (ORR), 1‐year recurrence rate, R0 resection rate and adverse events. Moreover, a meta‐analysis of 27 published literatures was also conducted for comparison.Results: In the analysis, 128 patients were studied, with 25% achieving pCR, 46.1% MPR, and 99.2% R0 resection. The 1‐, 2‐, and 3‐year OS rates were 91.41% (95% CI: 85.15%–95.63%), 75.00% (95% CI: 66.58%–82.23%) and 64.84% (95% CI: 55.91%–73.07%).ORR and DCR were 31.2% (95% CI: 23.31–39.99) and 64.1% (95% CI: 55.15%–72.38%), and the 1‐year recurrence rate was 26.7% (95% CI: 22.5%–38.1%). Treatment‐related events occurred in 96.1% but were acceptable. In a meta‐analysis of 27 studies with 1734 patients, pooled rates for pCR, MPR, ORR, DCR, and R0 resection were 29%, 52%, 71%, 97%, and 98%, respectively, with a 1‐year recurrence rate of 12%.Conclusion: NCIT is safe and provides potential survival benefits for patients with locally advanced ESCC. However, randomized phase 3 trial data is still needed.

1 August 2023 in Journal of Digestive Diseases
Verified
Journal Article
Closed access
YZYao Zhang
Yao Zhang
JLJiao Tao Liao
Jiao Tao Liao
YLYing Lin
Ying Lin
CLChang Liu
Chang Liu
ZWZhen Hua Wu
Zhen Hua Wu
JWJia Lei Wang
Jia Lei Wang